Concepts (108)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Calculi | 7 | 2022 | 339 | 2.190 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2022 | 350 | 1.350 |
Why?
|
| Diet, Vegetarian | 2 | 2022 | 8 | 1.100 |
Why?
|
| Cystinuria | 2 | 2021 | 13 | 1.030 |
Why?
|
| Nephrology | 1 | 2021 | 45 | 0.790 |
Why?
|
| Health Status Disparities | 1 | 2020 | 170 | 0.640 |
Why?
|
| Renal Agents | 1 | 2017 | 1 | 0.630 |
Why?
|
| Risk Reduction Behavior | 1 | 2017 | 98 | 0.590 |
Why?
|
| Ergocalciferols | 2 | 2007 | 38 | 0.560 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 827 | 0.490 |
Why?
|
| Vitamin D Deficiency | 2 | 2022 | 103 | 0.470 |
Why?
|
| Kidney Failure, Chronic | 2 | 2010 | 509 | 0.460 |
Why?
|
| Hypertension | 1 | 2021 | 1141 | 0.440 |
Why?
|
| Fibroblast Growth Factors | 1 | 2010 | 80 | 0.360 |
Why?
|
| Vitamins | 2 | 2022 | 81 | 0.330 |
Why?
|
| Parathyroid Hormone | 2 | 2022 | 218 | 0.320 |
Why?
|
| Alcohol Drinking | 2 | 2009 | 267 | 0.300 |
Why?
|
| Smoking | 2 | 2009 | 609 | 0.270 |
Why?
|
| Bone Diseases | 1 | 2006 | 54 | 0.270 |
Why?
|
| Bone Density Conservation Agents | 1 | 2005 | 45 | 0.260 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2005 | 70 | 0.260 |
Why?
|
| Calcium | 4 | 2022 | 1156 | 0.240 |
Why?
|
| Risk Factors | 5 | 2020 | 5417 | 0.240 |
Why?
|
| Diet | 3 | 2022 | 443 | 0.230 |
Why?
|
| Biomarkers | 3 | 2020 | 1718 | 0.220 |
Why?
|
| Humans | 18 | 2022 | 86643 | 0.220 |
Why?
|
| Drinking | 1 | 2022 | 34 | 0.210 |
Why?
|
| Aged | 8 | 2022 | 18415 | 0.210 |
Why?
|
| Wakefulness | 1 | 2012 | 134 | 0.210 |
Why?
|
| Perception | 1 | 2022 | 168 | 0.200 |
Why?
|
| Hypnotics and Sedatives | 1 | 2012 | 125 | 0.200 |
Why?
|
| Middle Aged | 9 | 2022 | 25028 | 0.190 |
Why?
|
| Renal Elimination | 1 | 2020 | 8 | 0.190 |
Why?
|
| Water-Electrolyte Balance | 1 | 2020 | 66 | 0.190 |
Why?
|
| Urodynamics | 1 | 2020 | 122 | 0.180 |
Why?
|
| Circadian Rhythm | 1 | 2012 | 303 | 0.180 |
Why?
|
| Respiration, Artificial | 1 | 2012 | 334 | 0.180 |
Why?
|
| Kidney | 2 | 2022 | 1241 | 0.170 |
Why?
|
| Treatment Outcome | 3 | 2020 | 7993 | 0.170 |
Why?
|
| Kidney Transplantation | 1 | 2006 | 849 | 0.170 |
Why?
|
| Sleep | 1 | 2012 | 444 | 0.160 |
Why?
|
| Colorectal Neoplasms | 1 | 2006 | 938 | 0.160 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2022 | 508 | 0.160 |
Why?
|
| Male | 9 | 2022 | 40965 | 0.150 |
Why?
|
| Disease Progression | 1 | 2021 | 1531 | 0.150 |
Why?
|
| Female | 9 | 2022 | 44532 | 0.140 |
Why?
|
| Chicago | 1 | 2020 | 1379 | 0.130 |
Why?
|
| Vitamin D | 2 | 2022 | 261 | 0.120 |
Why?
|
| Recurrence | 1 | 2017 | 1139 | 0.120 |
Why?
|
| Quality of Life | 1 | 2021 | 1585 | 0.120 |
Why?
|
| Prevalence | 1 | 2017 | 1239 | 0.110 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2013 | 8 | 0.110 |
Why?
|
| Incidence | 1 | 2017 | 1577 | 0.110 |
Why?
|
| Risk Assessment | 1 | 2020 | 2261 | 0.110 |
Why?
|
| Adult | 6 | 2022 | 25648 | 0.110 |
Why?
|
| Diuretics | 1 | 2013 | 124 | 0.110 |
Why?
|
| Calcium Channel Blockers | 1 | 2013 | 203 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2007 | 1961 | 0.110 |
Why?
|
| Retrospective Studies | 3 | 2020 | 8489 | 0.100 |
Why?
|
| Oxalates | 1 | 2010 | 48 | 0.100 |
Why?
|
| Minerals | 1 | 2010 | 22 | 0.090 |
Why?
|
| Hypercalciuria | 1 | 2010 | 47 | 0.090 |
Why?
|
| Kidney Tubules | 1 | 2010 | 94 | 0.090 |
Why?
|
| Age of Onset | 2 | 2009 | 310 | 0.090 |
Why?
|
| Bone and Bones | 1 | 2010 | 265 | 0.080 |
Why?
|
| Calcitriol | 1 | 2007 | 174 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2006 | 173 | 0.070 |
Why?
|
| Age Distribution | 1 | 2006 | 204 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2006 | 999 | 0.070 |
Why?
|
| Bone Density | 1 | 2006 | 209 | 0.060 |
Why?
|
| Pancreatic Neoplasms | 1 | 2009 | 645 | 0.060 |
Why?
|
| Lighting | 1 | 2012 | 32 | 0.050 |
Why?
|
| Sleep, REM | 1 | 2012 | 50 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2012 | 50 | 0.050 |
Why?
|
| Melatonin | 1 | 2012 | 47 | 0.050 |
Why?
|
| Registries | 1 | 2006 | 702 | 0.050 |
Why?
|
| Logistic Models | 1 | 2006 | 1186 | 0.050 |
Why?
|
| Polysomnography | 1 | 2012 | 151 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2009 | 1169 | 0.050 |
Why?
|
| Smartphone | 1 | 2022 | 36 | 0.050 |
Why?
|
| Chest Tubes | 1 | 2001 | 23 | 0.050 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2001 | 31 | 0.050 |
Why?
|
| Urinary Calculi | 1 | 2001 | 46 | 0.050 |
Why?
|
| Mass Screening | 1 | 2006 | 618 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 1801 | 0.050 |
Why?
|
| Drainage | 1 | 2001 | 157 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2006 | 977 | 0.050 |
Why?
|
| Cystine | 1 | 2020 | 14 | 0.050 |
Why?
|
| Electrocardiography | 1 | 2012 | 478 | 0.050 |
Why?
|
| Graft Rejection | 1 | 2006 | 1065 | 0.040 |
Why?
|
| Critical Illness | 1 | 2012 | 294 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2007 | 3640 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2012 | 373 | 0.040 |
Why?
|
| Consensus | 1 | 2020 | 335 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2007 | 4213 | 0.040 |
Why?
|
| United States | 2 | 2009 | 6672 | 0.040 |
Why?
|
| Time Factors | 2 | 2012 | 5210 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2007 | 6509 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 2501 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2013 | 162 | 0.030 |
Why?
|
| Animals | 1 | 2010 | 26582 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 1169 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2009 | 230 | 0.020 |
Why?
|
| Sex Factors | 1 | 2009 | 1054 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 1036 | 0.020 |
Why?
|
| Age Factors | 1 | 2009 | 1851 | 0.020 |
Why?
|
| Reoperation | 1 | 2001 | 597 | 0.010 |
Why?
|
| Aging | 1 | 2001 | 691 | 0.010 |
Why?
|